EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Long‐Term (5‐Years) Outcomes of Current Drug‐Eluting Stents in Percutaneous Coronary Intervention: A Network Meta‐Analysis of Randomized Controlled Trials

Aman Goyal iD, Humza Saeed iD, Sonia Hurjkaliani, Yusra Mashkoor iD, Abdullah iD, Gauranga Mahalwar, Ankur Kalra iD, Grant W Reed

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31668 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Aman Goyal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Coronary Artery Disease, Drug-Eluting Stents, Percutaneous Coronary Intervention. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Various drug‐eluting stents (DES) are currently used for percutaneous coronary intervention (PCI). However, long‐term trials reveal inconsistent results in head‐to‐head comparisons.

Aims

To conduct a network meta‐analysis of relevant trials to assess the performance of different DES currently used in PCI.

Methods

We systematically searched major databases for randomized controlled trials (RCTs) reporting 5‐year outcomes of currently used DES and conducted a network meta‐analysis using a frequentist random‐effects model with odds ratios (ORs) as effect measures. DES were ranked by P‐scores across several outcomes, with definite/probable stent thrombosis as the primary outcome. Statistical analyses were conducted in R software (v4.4.1), with significance set at p < 0.05.

Results

Twenty‐nine RCTs involving 46,502 patients were included in the analysis. Six currently used DES—Orsiro, Xience, Resolute, Nobori/BioMatrix, Synergy, and Promus—were analyzed. All comparisons showed nonsignificant results for outcomes at 5‐year follow‐up. Synergy ranked highest for definite/probable stent thrombosis ( p = 0.85), all‐cause mortality ( p = 0.76), cardiac death ( p = 0.87), and target vessel revascularization ( p = 0.91). Promus ranked best for any myocardial infarction (MI) ( p = 0.86), target lesion revascularization ( p = 0.93), and target vessel‐related MI ( p = 0.73). Nobori/BioMatrix ranked highest for target lesion failure ( p = 0.80). The newer generation Biofreedom stent also showed nonsignificant results but was excluded from the main analysis due to the availability of 5‐year outcomes from only one study. Global and local inconsistencies were nonsignificant for all outcomes and comparisons.

Conclusion

The analysis revealed no significant differences in 5‐year outcomes among the various DES. However, Synergy and Promus performed best for key outcomes such as stent thrombosis, mortality, and MI, suggesting their potential for favorable performance in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseDrug-Eluting StentsPercutaneous Coronary InterventionAgedFemaleHumansMaleMiddle AgedCoronary ThrombosisOdds RatioProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

cardiac deathdrug‐eluting stentsmyocardial infarctionnetwork meta‐analysisstent thrombosistarget lesion failuretarget lesion revascularization

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan.
  • Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Cardiology, Franciscan Health, Lafayette, Indiana, USA.
  • Krannert Cardiovascular Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

ORCID-Profile: Aman Goyal, Humza Saeed, Yusra Mashkoor, Abdullah, Ankur Kalra

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Goyal, A., Saeed, H., Hurjkaliani, S., Mashkoor, Y., Abdullah, Mahalwar, G., Kalra, A., & Reed, G. W. (2025). Long‐Term (5‐Years) Outcomes of Current Drug‐Eluting Stents in Percutaneous Coronary Intervention: A Network Meta‐Analysis of Randomized Controlled Trials. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31668

Vancouver

Goyal A, Saeed H, Hurjkaliani S, Mashkoor Y, Abdullah, Mahalwar G, et al. Long‐Term (5‐Years) Outcomes of Current Drug‐Eluting Stents in Percutaneous Coronary Intervention: A Network Meta‐Analysis of Randomized Controlled Trials. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31668

BibTeX
@article{Goyal2025,
  author = {Goyal, Aman and Saeed, Humza and Hurjkaliani, Sonia and Mashkoor, Yusra and Abdullah and Mahalwar, Gauranga and Kalra, Ankur and Reed, Grant W},
  title = {Long‐Term (5‐Years) Outcomes of Current Drug‐Eluting Stents in Percutaneous Coronary Intervention: A Network Meta‐Analysis of Randomized Controlled Trials},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31668}
}
Kostenlos starten →